These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30545782)

  • 1. Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients.
    Slevin AR; Hart MJ; Van Horn C; Rahman S; Samji NS; Szabo A; Rein L; Werner S; Saeian K
    J Am Pharm Assoc (2003); 2019; 59(1):51-56. PubMed ID: 30545782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
    Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J;
    Clin Infect Dis; 2020 Oct; 71(7):e115-e124. PubMed ID: 31677262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
    Serper M; Evon DM; Stewart PW; Lok AS; Amador J; Reeve BB; Golin CE; Fried MW; Reddy KR; Sterling RK; Sarkar S; Di Bisceglie AM; Lim JK; Nelson DR; Reau N
    J Gen Intern Med; 2020 Apr; 35(4):1011-1020. PubMed ID: 31659661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on the adherence to concomitant medications after initiation of treatment with direct-acting antiviral agents against hepatitis C virus.
    Guzman Ramos MI; Manzano-García M; Robustillo-Cortés MLA; Pineda JA; Morillo-Verdugo R
    Gastroenterol Hepatol; 2020 Oct; 43(8):418-425. PubMed ID: 32279937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
    Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
    Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.
    Tran AN; Sachdev R; Fricker ZP; Leber M; Zahorian T; Shah B; Nunes DP; Long MT
    Dig Dis Sci; 2018 Dec; 63(12):3241-3249. PubMed ID: 30078116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Beck KR; Kim N; Khalili M
    Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Backus LI; Belperio PS; Shahoumian TA; Mole LA
    Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Sikavi C; Najarian L; Saab S
    Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Marshall MC; Herrera JL
    Dig Dis Sci; 2018 Dec; 63(12):3228-3232. PubMed ID: 30128645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.